Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ADC Therapeutics, BioAtla deal

BioAtla's VivaMab therapeutic development division granted ADC Therapeutics rights to VivaMab's VM101 for hematologic

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE